0001415889-20-000092.txt : 20200109
0001415889-20-000092.hdr.sgml : 20200109
20200109161014
ACCESSION NUMBER: 0001415889-20-000092
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200102
FILED AS OF DATE: 20200109
DATE AS OF CHANGE: 20200109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Schneiderman Daniel H
CENTRAL INDEX KEY: 0001565536
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37853
FILM NUMBER: 20518277
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVE. SUITE 304
STREET 2: SUITE 207
CITY: BROOKLYN
STATE: NY
ZIP: 11226
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AzurRx BioPharma, Inc.
CENTRAL INDEX KEY: 0001604191
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
BUSINESS PHONE: 646-699-7855
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharma d'Azur, Inc.
DATE OF NAME CHANGE: 20140331
4
1
form4-01092020_040101.xml
X0306
4
2020-01-02
0001604191
AzurRx BioPharma, Inc.
AZRX
0001565536
Schneiderman Daniel H
760 PARKSIDE AVE DOWNSTATE
BIOTECHNOLOGY INCUBATOR STE 304
BROOKLYN
NY
11226
false
true
false
false
CHIEF FINANCIAL OFFICER
Options
1.03
2020-01-02
4
A
0
335006
A
2030-01-02
Common Stock
335006
335006
D
Options granted in connection with the Reporting Person's appointment as Chief Financial Officer of the Issuer. The options will vest in three equal annual installments commencing on the first anniversary of the grant date, becoming fully vested on January 2, 2023.
/s/ Daniel Schneiderman
2020-01-08